January 19, 2017
Astellas Pharma is the latest company to announce its participation in Access Accelerated, a global, multi-stakeholder initiative to advance access to non-communicable disease (NCD) prevention, diagnostics and treatment in low-income and lower-middle income countries.
Access Accelerated comprises 22 leading pharmaceutical companies, who, in collaboration with the World Bank Group and the Union for International Cancer Control (UICC), will work towards the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by one-third by 2030.
The contributing companies include Almirall, Astellas, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Eli Lilly and Company, EFPIA, GlaxoSmithKline, The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Johnson & Johnson, JPMA, Menarini, Merck, MSD, Novartis, Pfizer, PhRMA, Roche, Sanofi, Shionogi, Sumitomo Dainippon, Takeda and UCB.
IFPMA will act as the Secretariat for Access Accelerated.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.